Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
LABU vs BIB
Shared holdings
113
LABU covered by BIB
33.99%
BIB covered by LABU
33.99%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
LABU (April 30, 2026)
| Security | Weight | |
|---|---|---|
| DREYFUS GOVT CASH MGMT FUND | 7.43% | |
| US ULTRA BOND CBT Sep25 | 7.26% | |
| GOLDMAN FINL SQ TRSRY INST 506 | 6.27% | |
| GOLDMAN SACHS FIN GOV 465 INSTITUT | 1.71% | |
| APELLIS PHARMACEUTICALS INC | 1.44% | |
| REVOLUTION MEDICINES INC | 1.27% | |
| TRAVERE THERAPEUTICS INC | 1.25% | |
| ARROWHEAD PHARMACEUTICALS INC | 1.11% | |
| TWIST BIOSCIENCE CORP | 1.10% | |
| SUMMIT THERAPEUTICS INC | 1.09% | |
| ALKERMES PLC | 1.07% | |
| TG THERAPEUTICS INC | 1.06% | |
| MADRIGAL PHARMACEUTICALS INC | 1.06% | |
| BEAM THERAPEUTICS INC | 1.02% | |
| APOGEE THERAPEUTICS INC | 0.98% | |
| SCHOLAR ROCK HOLDING CORP | 0.95% | |
| PRAXIS PRECISION MEDICINES INC | 0.95% | |
| EXELIXIS INC | 0.94% | |
| MIRUM PHARMACEUTICALS INC | 0.93% | |
| UNITED THERAPEUTICS CORP DEL | 0.92% | |
| NATERA INC | 0.92% | |
| CELCUITY INC | 0.92% | |
| CRISPR Therapeutics A.G. Series A | 0.92% | |
| KRYSTAL BIOTECH INC | 0.91% | |
| PROTAGONIST THERAPEUTICS INC | 0.90% | |
| NEUROCRINE BIOSCIENCES INC | 0.89% | |
| INCYTE CORP | 0.89% | |
| CG ONCOLOGY INC | 0.89% | |
| CYTOKINETICS INC | 0.89% | |
| NUVALENT INC-A | 0.88% | |
| IONIS PHARMACEUTICALS INC | 0.88% | |
| BRIDGEBIO PHARMA INC | 0.88% | |
| VAXCYTE INC | 0.88% | |
| KYMERA THERAPEUTICS INC | 0.88% | |
| BIOGEN INC | 0.87% | |
| COGENT BIOSCIENCES INC | 0.87% | |
| PTC THERAPEUTICS INC | 0.87% | |
| INSMED INC | 0.86% | |
| ALNYLAM PHARMACEUTICALS INC | 0.85% | |
| ROIVANT SCIENCES | 0.85% | |
| HALOZYME THERAPEUTICS INC | 0.84% | |
| ARCUTIS BIOTHERAPEUTICS INC | 0.83% | |
| SPYRE THERAPEUTICS INC | 0.83% | |
| SOLENO THERAPEUTICS INC | 0.82% | |
| ABBVIE INC | 0.82% | |
| AMGEN INC | 0.81% | |
| REGENERON PHARMACEUTICALS INC | 0.80% | |
| ULTRAGENYX PHARMA INC | 0.80% | |
| ACADIA PHARMACEUTICALS INC | 0.80% | |
| RHYTHM PHARMACEUTICALS INC | 0.80% |
BIB (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| US ULTRA BOND CBT Sep25 | 19.64% | |
| GILEAD SCIENCES INC | 6.95% | |
| VERTEX PHARMACEUTICALS INC | 6.72% | |
| AMGEN INC | 6.59% | |
| Repurchase Agreement | 6.10% | |
| REGENERON PHARMACEUTICALS INC | 4.36% | |
| ALNYLAM PHARMACEUTICALS INC | 2.37% | |
| Invesco Government & Agency Portfolio, Institutional Class | 1.94% | |
| INSMED INC | 1.72% | |
| BIOGEN INC | 1.52% | |
| ARGENX SE SPONSORED ADR | 1.20% | |
| UNITED THERAPEUTICS CORP DEL | 1.17% | |
| MODERNA INC | 1.13% | |
| ILLUMINA INC | 1.11% | |
| ROIVANT SCIENCES LTD | 1.09% | |
| INCYTE CORP | 1.07% | |
| ROYALTY PHARMA PLC | 1.07% | |
| REVOLUTION MEDICINES INC | 1.06% | |
| VIATRIS INC | 0.93% | |
| Ascendis Pharma A/S | 0.77% | |
| NEUROCRINE BIOSCIENCES INC | 0.71% | |
| IONIS PHARMACEUTICALS INC | 0.71% | |
| SANOFI SPON ADR | 0.69% | |
| BRIDGEBIO PHARMA INC | 0.69% | |
| MEDPACE HOLDINGS INC | 0.69% | |
| SUMMIT THERAPEUTICS INC | 0.67% | |
| GUARDANT HEALTH INC | 0.66% | |
| BIOMARIN PHARMACEUTICAL INC | 0.64% | |
| EXELIXIS INC | 0.64% | |
| JAZZ PHARMA PLC | 0.62% | |
| BIONTECH SE ADR | 0.60% | |
| BEONE MEDICINES LTD ADR | 0.54% | |
| MADRIGAL PHARMACEUTICALS INC | 0.53% | |
| IMMUNITYBIO INC | 0.52% | |
| TEMPUS AI INC-A | 0.50% | |
| ARROWHEAD PHARMACEUTICALS INC | 0.46% | |
| PRAXIS PRECISION MEDICINES INC | 0.45% | |
| AXSOME THERAPEUTICS INC | 0.45% | |
| HALOZYME THERAPEUTICS INC | 0.44% | |
| VAXCYTE INC | 0.44% | |
| KRYSTAL BIOTECH INC | 0.43% | |
| CYTOKINETICS INC | 0.41% | |
| NUVALENT INC-A | 0.40% | |
| Abivax SA SPONSORED ADS | 0.39% | |
| ARCELLX INC | 0.36% | |
| KYMERA THERAPEUTICS INC | 0.35% | |
| RHYTHM PHARMACEUTICALS INC | 0.33% | |
| COGENT BIOSCIENCES INC | 0.32% | |
| PROTAGONIST THERAPEUTICS INC | 0.31% | |
| CRISPR THERAPEUTICS AG | 0.31% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.